Cost and economic evidence of stroke technology-assisted rehabilitation: a scoping review
10 affiliations
- 1Singapore-ETH Centre, Future Health Technologies Programme, CREATE Campus, Singapore, 138602 Singapore
- 2Rehabilitation Engineering Laboratory, Department of Health Sciences and Technology, ETH Zurich, Zurich, 8092 Switzerland
- 3Rehabilitation Research Institute of Singapore, Nanyang Technological University, Singapore, 308232 Singapore
- 4Institute of Rehabilitation Excellence, Tan Tock Seng Hospital Rehabilitation Centre, Singapore, 307382 Singapore
- 5Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117597 Singapore
- 6Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 308232 Singapore
- 7Programme in Health Services and Systems Research, Duke-NUS Medical School, National University of Singapore, Singapore, 169857 Singapore
- 8Department of Internal Medicine (General Internal Medicine), Duke University Medical School, Durham, NC 27710 USA
- 9Department of Computer Science and Artificial Intelligence, University of Technology Nuremberg, 90461 Nuremberg, Germany
- 10Neural Control of Movement Laboratory, Department of Health Sciences and Technology, ETH Zurich, Zurich, 8092 Switzerland
Abstract
Introduction: In recent years, the growing demand for cost-effective rehabilitation after stroke has motivated the development of novel technologies to support high-intensity rehabilitation. However, available knowledge on the economic benefits of stroke technology-assisted rehabilitation (TAR) is relatively scarce and fragmented. Therefore, this scoping review aimed to review evidence on the economic benefits of TAR in laboratory, clinical, and home settings, as well as the methodologies used to evaluate these outcomes.
Methods: A systematic search of four electronic bibliographic databases and two additional grey literature/ economic evidence sources (until 03 June 2026) identified 6469 records. Following predefined inclusion and exclusion criteria, 44 records were considered for further analysis. Additionally, 21 records were identified through a citation search.
Results: In total, 65 articles reporting TAR-related costs were included, but only a few of these studies reported cost analyses (mostly cost comparisons). Firstly, of the 38 studies conducted in laboratory settings, only one reported a formal TAR-related cost analysis. Secondly, out of 16 studies reporting costs, 11 studies performed cost analysis for TAR in clinical settings. Of these, the majority (six) estimated TAR to be equally effective or even superior (one) and cheaper than conventional therapy (CT) in the clinic, but only when TAR enabled the therapist to treat several stroke survivors in parallel. This was captured using the relative therapist-to-patient ratio (rT/P), indicating that staffing and supervision models were more important than device cost. Lastly, seven of 13 studies conducted TAR-related cost analysis in a home setting. Three studies suggested that TAR may be economically beneficial compared with CT in the clinic.
Conclusion: Empirical findings suggest that TAR may generate cost savings compared to CT in the clinic, particularly when rT/P is < 0.5. However, the current evidence is sparse, with limited comparability and generalisability due to heterogeneous TAR modalities, comparators and cost-calculation methods.
Clinical trial number: Not applicable.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12913-026-15267-7.
Related
- Rhythm-centred music interventions for motor coordination and rehabilitation: a scoping review of mechanisms, design principles, and technology-assisted assessment.
- Implementing robotic-assisted therapy in stroke rehabilitation: a structured narrative review of evidence and technology adoption barriers in Indonesia.
- Technology-Assisted Cognitive Rehabilitation in Parkinson’s Disease: A Systematic Review of Cognitive, Psychological, and Implementation Outcomes
- Trace Element Concentrations in Follicular Fluid and Serum and Their Association with Assisted Reproductive Technology Outcomes: Preliminary Evidence
- Technology-Assisted Rehabilitation Gym for at-home Training (TARGeT) for stroke survivors: A study protocol for evaluating feasibility, safety, usability, clinical benefit, and costs
BibTeX
@article{samkharadze2026cost,
title = {{Cost and economic evidence of stroke technology-assisted rehabilitation: a scoping review}},
author = {Tengiz Samkharadze and Olivier Lambercy and Roger Gassert and Karen Sui Geok Chua and David Bruce Matchar and Simone Kager and Nicole Wenderoth and Hsiao-ju Cheng},
journal = {BMC Health Services Research},
year = {2026},
month = aug,
doi = {10.1186/s12913-026-15267-7},
url = {https://doi.org/10.1186/s12913-026-15267-7},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cost and economic evidence of stroke technology-assisted rehabilitation: a scoping review
AU - Tengiz Samkharadze
AU - Olivier Lambercy
AU - Roger Gassert
AU - Karen Sui Geok Chua
AU - David Bruce Matchar
AU - Simone Kager
AU - Nicole Wenderoth
AU - Hsiao-ju Cheng
PY - 2026
DA - 2026/08/11
JO - BMC Health Services Research
DO - 10.1186/s12913-026-15267-7
UR - https://doi.org/10.1186/s12913-026-15267-7
AB - Introduction: In recent years, the growing demand for cost-effective rehabilitation after stroke has motivated the development of novel technologies to support high-intensity rehabilitation. However, available knowledge on the economic benefits of stroke technology-assisted rehabilitation (TAR) is relatively scarce and fragmented. Therefore, this scoping review aimed to review evidence on the economic benefits of TAR in laboratory, clinical, and home settings, as well as the methodologies used to evaluate these outcomes. Methods: A systematic search of four electronic bibliographic databases and two additional grey literature/ economic evidence sources (until 03 June 2026) identified 6469 records. Following predefined inclusion and exclusion criteria, 44 records were considered for further analysis. Additionally, 21 records were identified through a citation search. Results: In total, 65 articles reporting TAR-related costs were included, but only a few of these studies reported cost analyses (mostly cost comparisons). Firstly, of the 38 studies conducted in laboratory settings, only one reported a formal TAR-related cost analysis. Secondly, out of 16 studies reporting costs, 11 studies performed cost analysis for TAR in clinical settings. Of these, the majority (six) estimated TAR to be equally effective or even superior (one) and cheaper than conventional therapy (CT) in the clinic, but only when TAR enabled the therapist to treat several stroke survivors in parallel. This was captured using the relative therapist-to-patient ratio (rT/P), indicating that staffing and supervision models were more important than device cost. Lastly, seven of 13 studies conducted TAR-related cost analysis in a home setting. Three studies suggested that TAR may be economically beneficial compared with CT in the clinic. Conclusion: Empirical findings suggest that TAR may generate cost savings compared to CT in the clinic, particularly when rT/P is < 0.5. However, the current evidence is sparse, with limited comparability and generalisability due to heterogeneous TAR modalities, comparators and cost-calculation methods. Clinical trial number: Not applicable. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12913-026-15267-7.
SN - 1472-6963
ER -